Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Phase 2b HAL-CINP-203 ongoing for CINP; FDA Fast Track designation for CINP. Company developing synthetically manufactured TTX for Phase 3 (2027) with FDA engagement planned 2H 2026. Potential expansion into non-neuropathic cancer pain and acute post-surgical pain. Going-concern warning: cash funds operations only into Q4 2026.
SP16
Preclinical · ActiveModality: peptide (17 amino acid, IV formulation)
Target LRP1
Partnerships Serpin Pharma Inc./Rejuvenation Labs: royalty-free global license (equity consideration; expensed as acquired IPR&D)
Status note First-in-class LRP1 agonist. FDA accepted IND for IV SP16 for CINP; Phase 1b safety evaluation in cancer patients funded by an NCI grant (no expense to company), recruitment/dosing expected 2H 2026.
IMC-1
Stage not disclosed · ActiveModality: small molecule (fixed-dose combination of a nucleoside analog and celecoxib)
Partnerships PRIDCor Therapeutics: exclusive global license; PRIDCor funds all development (tiered royalties up to 15%, 10% of Series A, 9% of future raises, payments capped at $100M; $100,000 first payment received July 2026)
Indications
Fibromyalgia(Stage not disclosed)
Status note Partnered out-licensed program; company has no further R&D or marketing obligations. Proceeds above $100K subject to CVR pass-through (87.75% to CVR holders).
IMC-2
Stage not disclosed · ActiveModality: small molecule (combination of valacyclovir and celecoxib)
Partnerships PRIDCor Therapeutics: exclusive global license (same terms as IMC-1)
Indications
Long-COVID(Stage not disclosed)
Status note Partnered out-licensed program; company has no further R&D or marketing obligations.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.